Home Healthcare Biotechnology Dengue Vaccine Market

Dengue Vaccine Market Size, Share & Trends Analysis Report By Product (Dengvaxia, Qdenga, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Government & Public Health Agencies, Hospitals & Specialty Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 15, 2025 | Author: Debashree B | Format: | Report Code: SR7557DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Dengue Vaccine Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Dengvaxia
    2. Qdenga
    3. Others
  2. Dengue Vaccine Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parenteral
    3. Others
  3. Dengue Vaccine Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Government & Public Health Agencies
    2. Hospitals & Specialty Clinics
    3. Others
  4. Regional Dengue Vaccine Market
    1. North America
      1. North America Dengue Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Dengvaxia
        2. Qdenga
        3. Others
      2. North America Dengue Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Others
      3. North America Dengue Vaccine Market By End User 2022-2034 (USD MILLION/ Units)
        1. Government & Public Health Agencies
        2. Hospitals & Specialty Clinics
        3. Others
      4. U.S.
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      5. Canada
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
    2. Europe
      1. Europe Dengue Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Dengvaxia
        2. Qdenga
        3. Others
      2. Europe Dengue Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Others
      3. Europe Dengue Vaccine Market By End User 2022-2034 (USD MILLION/ Units)
        1. Government & Public Health Agencies
        2. Hospitals & Specialty Clinics
        3. Others
      4. U.K.
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      5. Germany
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      6. France
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      7. Spain
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      8. Italy
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      9. Russia
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      10. Nordic
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      11. Benelux
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      12. Rest of Europe
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
    3. APAC
      1. APAC Dengue Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Dengvaxia
        2. Qdenga
        3. Others
      2. APAC Dengue Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Others
      3. APAC Dengue Vaccine Market By End User 2022-2034 (USD MILLION/ Units)
        1. Government & Public Health Agencies
        2. Hospitals & Specialty Clinics
        3. Others
      4. China
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      5. Korea
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      6. Japan
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      7. India
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      8. Australia
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      9. Taiwan
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      10. South East Asia
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      11. Rest of Asia-Pacific
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
    4. Middle East and Africa
      1. Middle East and Africa Dengue Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Dengvaxia
        2. Qdenga
        3. Others
      2. Middle East and Africa Dengue Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Others
      3. Middle East and Africa Dengue Vaccine Market By End User 2022-2034 (USD MILLION/ Units)
        1. Government & Public Health Agencies
        2. Hospitals & Specialty Clinics
        3. Others
      4. UAE
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      5. Turkey
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      6. Saudi Arabia
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      7. South Africa
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      8. Egypt
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      9. Nigeria
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      10. Rest of MEA
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
    5. LATAM
      1. LATAM Dengue Vaccine Market By Product 2022-2034 (USD MILLION/ Units)
        1. Dengvaxia
        2. Qdenga
        3. Others
      2. LATAM Dengue Vaccine Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Others
      3. LATAM Dengue Vaccine Market By End User 2022-2034 (USD MILLION/ Units)
        1. Government & Public Health Agencies
        2. Hospitals & Specialty Clinics
        3. Others
      4. Brazil
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      5. Mexico
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      6. Argentina
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      7. Chile
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      8. Colombia
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
      9. Rest of LATAM
        1. Dengvaxia
        2. Qdenga
        3. Others
        4. Oral
        5. Parenteral
        6. Others
        7. Government & Public Health Agencies
        8. Hospitals & Specialty Clinics
        9. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.